In vivo release and retinal safety of intravitreal implants of thalidomide in rabbit eyes and antiangiogenic effect on the chorioallantoic membrane

References

• Qazi Y, Maddula S, Ambati BK. Mediators of ocular angiogenesis. J Genet 2009;88:495–515
   PubMed Web of Science ®Google Scholar
• Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222–43
   PubMed Web of Science ®Google Scholar
• Saati S, Agrawal RN, Louie S, et al. Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits. Graefes Arch Clin Exp Ophthalmol 2010;248:457–66
   PubMed Web of Science ®Google Scholar
• Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001;52:37–48
   PubMed Web of Science ®Google Scholar
• Ogura Y. Drug delivery to the posterior segments of the eye. Adv Drug Deliv Rev 2001;52:1–3
   PubMed Web of Science ®Google Scholar
• Fialho SL, Rêgo MGB, Cardillo JA, et al. Implantes biodegradáveis destinados à administração intra-ocular. Arq Bras Oftalmol 2003;66:891–6
   Google Scholar
• Rabinowitz R, Katz G, Rosner M, et al. The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:843–8
   PubMed Web of Science ®Google Scholar
• Aydoğan S, Çeliker U, Türkçüoğlu P, et al. The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-α levels in retinal ischemia/reperfusion injury. Graefes Arch Clin Exp Ophthalmol 2008;246:363–8
   PubMed Web of Science ®Google Scholar
• Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies: their potential in cancer management. Oncol Targets Ther 2010;3:69–82
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–31
   PubMed Web of Science ®Google Scholar
• CATT Research Group, Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–908
   PubMed Web of Science ®Google Scholar
• Jorge R, Oliveira RS, Messias A, et al. Ranibizumab for retinal neovascularization. Ophthalmology 2011;118:1004–5
   PubMed Web of Science ®Google Scholar
• Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236:461–6
   PubMed Web of Science ®Google Scholar
• Spraul CW, Kaven C, Kampmeier J, et al. Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro. Curr Eye Res 1999;19:483–90
   PubMed Web of Science ®Google Scholar
• Kaven C, Spraul CW, Zavazava N, et al. Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro. Ophthalmologica 2001;215:284–9
   PubMed Web of Science ®Google Scholar
• Fialho SL, Rêgo MGB, Siqueira RC, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res 2006;31:525–34
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 2010;67:217–23
   PubMed Web of Science ®Google Scholar
• The United States Pharmacopeia. 32 ed. (USP 32). Rockville: United States Pharmacopeial Convention Inc. CD-ROM (Insight Publishing Productivity); 2009
   Google Scholar
• Nowak-Sliwinska P, Ballini JP, Wagnières G, et al. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc Res 2010;79:21–8
   PubMed Web of Science ®Google Scholar
• Naka KI, Rushton WA. S-potentials from luminosity units in the retina of fish (Cyprinidae). J Physiol 1966;185:587–99
   PubMed Web of Science ®Google Scholar
• Fujita Y, Abe R, Shimizu H. Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des 2008;14:3820–34
   PubMed Web of Science ®Google Scholar
• Silva-Cunha A, Fialho SL, Naud MC, et al. Poly-e-caprolactone intravitreous devices: an in vivo study. Invest Ophthalmol Vis Sci 2009;50:2312–18
   PubMed Web of Science ®Google Scholar
• Fialho SL, Behar-Cohen F, Silva-Cunha A. Dexamethasone-loaded poly(e-caprolactone) intravitreal implants: a pilot study. Eur J Pharm Biopharm 2008;68:637–46
   PubMed Web of Science ®Google Scholar
• Sharma S, Ghoddoussi M, Gao P, et al. A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res 2001;21:3829–37
   PubMed Web of Science ®Google Scholar
• Eter N, Spitznas M. DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture. Br J Ophthalmol 2002;86:1303–5
   PubMed Web of Science ®Google Scholar
• Hyakkoku K, Nakajima Y, Izuta H, et al. Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice. Neuroscience 2009;159:760–9
   PubMed Web of Science ®Google Scholar
• Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996;17:93–102
   PubMed Web of Science ®Google Scholar
• Colthurst MJ, Williams RL, Hiscott PS, et al. Biomaterials used in the posterior segment of the eye. Biomaterials 2000;21:649–65
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453–60
   PubMed Web of Science ®Google Scholar
• Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveítes. Clin Ophthalmol 2011;5:1613–21
   PubMedGoogle Scholar
• Moisseiev E, Goldstein M, Waisbourd M, et al. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye 2013;27:65–71
   PubMed Web of Science ®Google Scholar